Framus, ,Investing, Igober , Ana , Mugi , etc., etc etc
Os importa echarle una ojeadita a ACST que ha publicado este articulo citando Lovaza de AMRN diciendo que consigue mejor biodisponibilidad y mejores resultados , si bien desde AT está haciendo una Taza con Asa y por tanto ya a punto de despegar además su Short Interest ha caído en cascada o notablemente en cada reporte quincenal, y llama la atención que los osos se retiran más y más en la medida que se define el asa derecha de la Taza y por tanto a punto, para mi ,,de breakout y se lee en STw ese misma opinión
Y si esta va a seguir la trayectoria de ARMN mas reciente , no, nos la debiamos perder
-
Acasti’s open-label, randomized, four-way, cross-over, bioavailability study compared CaPre, given as a single dose of 4 grams in fasting and fed states, with the approved hypertriglyceridemia drug LOVAZA (omega-3-acid ethyl esters or OM3-EE) in 56 healthy volunteers. Among subjects in the fasting state, CaPre demonstrated better bioavailability than LOVAZA, as measured by blood levels of EPA and DHA.
The article concluded: “Among subjects in the fasted state, the test product (CaPre) demonstrated greater bioavailability of EPA and DHA in the form of free fatty acids and esterified to phospholipids as compared to OM3-EE (reference product). Bioavailability with OM3-EE was drastically reduced in the fasted state compared to administration with a high-fat meal. Since patients with severe HTG should adhere to a low-fat diet, these findings suggest preserved exposure, and perhaps retained efficacy, in patients taking OM3-PL/FFA in the fasted state or with a low-fat diet.”
This might be important for clinical use in treating patients with elevated blood lipids to prevent heart attacks and strokes.”
We are very pleased to have our study published in a leading peer reviewed journal, which further validates the superior bioavailability of CaPre when compared to the omega-3 ethyl ester drug, LOVAZA, in conditions which we believe are more relevant for patients with severe HTG
/pr/17461402-acasti-pharma-announces-publication-capre-bioavailability-study-leading-peer-reviewed-journal